Miniatura

Fitxers

Busschots_D_BMC_Infect_Dis_2020.pdf (655.23 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-02-27

Llicència de publicació

cc by (c) Busschots et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/159619

Eliminating viral hepatitis C in Belgium: the micro-elimination approach

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1186/s12879-020-4898-y

Resum

Background: Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a ‘Hepatitis C Plan’ since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure. Methods: We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups. Results: Eleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients. Conclusions: Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium.

Matèries

Hepatitis C, Terapèutica

Matèries (anglès)

Hepatitis C, Therapeutics

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)

Citació

BUSSCHOTS, Dana, TOGHANIAN, Samira, BIELEN, Rob, SALOMONSSON, Stina, KOC, Özgür m., HENDRICKX, Greet, JADOUL, Michel, NEVENS, Frederick, SOKAL, Etienne, BRIXKO, Christian, PEERLINCK, Kathelijne, APERS, Ludwig, ROBAEYS, Geert, LAZARUS, Jeffrey v.. Eliminating viral hepatitis C in Belgium: the micro-elimination
                approach. _BMC Infectious Diseases_. 2020. Vol. 20, núm. 181. [consulta: 13 de gener de 2026]. ISSN: 1471-2334. [Disponible a: https://hdl.handle.net/2445/159619]

Exportar metadades

JSON - METS

Compartir registre